Oxygenta Pharmaceutical Ltd Financials
Company Logo

Oxygenta Pharmaceutical Ltd Financial Statement

Oxygenta Pharmaceutical Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue12.64
Operating Expense14.40
Net Profit-1.36
Net Profit Margin-10.76
Earning Per Share-0.39
EBIDTA-0.30
Effective Tax RateTBA

Oxygenta Pharmaceutical Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual39.64
Operating Expenses Annual49.34
Operating Profit Annual-9.62
Interest Annual1.59
Depreciation2.66
Net Profit Annual-3.48
Tax Annual-10.39

Oxygenta Pharmaceutical Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.11
Cash Flow from Operations-13.05
Cash Flow from Investing-4.09
Cash Flow from Financing17.13
Cash Flow at the End0.10

Oxygenta Pharmaceutical Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)-24.27
PBIT Margin (%)-30.98
PBT Margin (%)-11.50
Net PROFIT Margin (%)-8.78
Return On Networth / Equity (%)TBA
Return On Networth /Employed (%)TBA
Return On Assets (%)-10.97
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)1.25

Oxygenta Pharmaceutical Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual29.36
Total Current Assets Annual24.11
Non Current Assets Annual39.09
Total Shareholders Funds Annual-20.12
Total Assets Annual63.19

Oxygenta Pharmaceutical Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Nov 5, 2024, Oxygenta Pharmaceutical Ltd has a market capitalization of 97.07 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Oxygenta Pharmaceutical Ltd is debt-free with a debt-to-equity ratio of -2.84.
In FY 2023 , Oxygenta Pharmaceutical Ltd recorded a total revenue of approximately 39.64 Cr marking a significant milestone in the company's financial performance.
Oxygenta Pharmaceutical Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.5% and -0.2% annually, respectively..
Oxygenta Pharmaceutical Ltd's current PE ratio is -27.89.
Oxygenta Pharmaceutical Ltd's ROCE averaged -24.5% from the FY ending March 2022 to 2024, with a median of -33.1%. It peaked at -0.5% in March 2022, reflecting strong capital efficiency over the period..
Oxygenta Pharmaceutical Ltd's latest EBIT is Rs. -12.28 Cr, surpassing the average EBIT of Rs. -7.24 Cr over the 5 years..